GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Tangible Book per Share

Virax Biolabs Group (Virax Biolabs Group) Tangible Book per Share : $3.29 (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Virax Biolabs Group's tangible book value per share for the quarter that ended in Sep. 2023 was $3.29.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Virax Biolabs Group Tangible Book per Share Historical Data

The historical data trend for Virax Biolabs Group's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Tangible Book per Share Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Tangible Book per Share
-0.93 -0.57 -0.86 5.76

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Tangible Book per Share Get a 7-Day Free Trial -0.70 -0.86 3.77 5.76 3.29

Competitive Comparison of Virax Biolabs Group's Tangible Book per Share

For the Biotechnology subindustry, Virax Biolabs Group's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virax Biolabs Group's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Price-to-Tangible-Book falls into.



Virax Biolabs Group Tangible Book per Share Calculation

Virax Biolabs Group's Tangible Book Value Per Share for the fiscal year that ended in Mar. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(9.126-0-0.178)/1.55471
=5.76

Virax Biolabs Group's Tangible Book Value Per Share for the quarter that ended in Sep. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(6.333-0-0.375)/1.81154
=3.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Virax Biolabs Group  (NAS:VRAX) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Virax Biolabs Group Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Virax Biolabs Group (Virax Biolabs Group) Business Description

Traded in Other Exchanges
N/A
Address
20 North Audley Street, London, GBR, W1K 6LX
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.